Scalene Cybernetics Limited, a leader in innovative medical technology has now introduced the Haemoseis 3D Vasculography. It has the capability to provide non-invasively, over 60 vital parameters which will help empower the doctors with more information of the cardiovascular system.

The device can be used for early assessment, diagnosis, management and prognosis of life-threatening cardiovascular diseases.

According to Dr Rajah Vijay Kumar, chairman and managing director, Scalene Cybernetics, the device will revolutionize diagnostics. India has reached a stage in medical diagnostics where new technologies need to be introduced to make sure that we don’t miss the bus, while competing with other countries. Haemoseis, can help bring two related but rarely interconnected disciplines of cardiology and Vasculography together to help manage life-threatening diseases at an early stage.

The device is designed to provide a complete vital Haemodynamic picture of the heart, lungs and blood vessels. The cardiovascular information will be displayed to the related departments of outpatient clinic, emergency rooms, intensive care units, cath labs and operation theaters.

This new technology of Haemoseis evolves to reduce risks associated with proper diagnosis, especially for the poor and the disadvantaged. The machine reduces the delay in access to hospital, improves affordability of urgent care and can reduce morbidity and mortality from acute coronary syndromes, stated Dr. Kumar who has made considerable efforts in neural networks in medical diagnosis and engineering.

Scalene Cybernetics Limited is an associate company of Organization de Scalene, with offices at Malaysia, Singapore, Netherlands, Dubai, North America and several European countries. Its focus areas include medical nanotechnology, artificial intelligence, environmental sciences, power engineering and energy generation among others. Its nodal R&D centre is based in Bangalore, is working towards break-through scientific innovation. The company’s product Cytotron used to control pain in cancer and osteoarthritis bagged the CE certification from Underwriters Laboratories (UL) in August 2009.